Serveur d'exploration Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Non‐human viruses developed as therapeutic agent for use in humans

Identifieur interne : 000C78 ( Main/Exploration ); précédent : 000C77; suivant : 000C79

Non‐human viruses developed as therapeutic agent for use in humans

Auteurs : Danijela Koppers-Lalic [Pays-Bas] ; Rob C. Hoeben [Pays-Bas]

Source :

RBID : ISTEX:ABA0CDBD2DCC8AA0A11B54C1B445C00EBB8EA660

English descriptors

Abstract

Viruses usually infect a restricted set of host species, and only in rare cases does productive infection occur outside the natural host range. Infection of a new host species can manifest as a distinct disease. In this respect, the use of non‐human viruses in clinical therapy may be a cause for concern. It could provide the opportunity for the viruses to adapt to the new host and be transferred to the recipient's relatives or medical caretakers, or even to the normal host species. Such environmental impact is evidently undesirable. To forecast future clinical use of non‐human viruses, a literature study was performed to identify the viruses that are being considered for application as therapeutic agents for use in humans. Twenty‐seven non‐human virus species were identified that are in (pre)clinical development, mainly as oncolytic agents. For risk management, it is essential that the potential environmental consequences are assessed before initiating clinical use, even if the virus is not formally classified as a genetically modified organism. To aid such assessment, each of these viruses was classified in one of five relative environmental risk categories, ranging from “Negligible” to “Very High”. Canary pox virus and the Autographa californica baculovirus were assigned a “Negligible” classification, and Seneca Valley virus, murine leukemia virus, and Maraba virus to the “High” category. A complicating factor in the classification is the scarcity of publicly available information on key aspects of virus biology in some species. In such cases the relative environmental risk score was increased as a precaution. Copyright © 2011 John Wiley & Sons, Ltd.

Url:
DOI: 10.1002/rmv.694


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Non‐human viruses developed as therapeutic agent for use in humans</title>
<author>
<name sortKey="Koppers Alic, Danijela" sort="Koppers Alic, Danijela" uniqKey="Koppers Alic D" first="Danijela" last="Koppers-Lalic">Danijela Koppers-Lalic</name>
</author>
<author>
<name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ABA0CDBD2DCC8AA0A11B54C1B445C00EBB8EA660</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/rmv.694</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-N6DD6QZZ-K/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000750</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000750</idno>
<idno type="wicri:Area/Istex/Curation">000730</idno>
<idno type="wicri:Area/Istex/Checkpoint">000085</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000085</idno>
<idno type="wicri:doubleKey">1052-9276:2011:Koppers Alic D:non:human:viruses</idno>
<idno type="wicri:Area/Main/Merge">000C80</idno>
<idno type="wicri:Area/Main/Curation">000C78</idno>
<idno type="wicri:Area/Main/Exploration">000C78</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Non‐human viruses developed as therapeutic agent for use in humans</title>
<author>
<name sortKey="Koppers Alic, Danijela" sort="Koppers Alic, Danijela" uniqKey="Koppers Alic D" first="Danijela" last="Koppers-Lalic">Danijela Koppers-Lalic</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Molecular Cell Biology, Mailstop S1‐P, Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName>
<settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Molecular Cell Biology, Mailstop S1‐P, Leiden University Medical Center, Leiden</wicri:regionArea>
<placeName>
<settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Pays-Bas</country>
</affiliation>
<affiliation></affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Pays-Bas</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Reviews in Medical Virology</title>
<title level="j" type="alt">REVIEWS IN MEDICAL VIROLOGY</title>
<idno type="ISSN">1052-9276</idno>
<idno type="eISSN">1099-1654</idno>
<imprint>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="227">227</biblScope>
<biblScope unit="page" to="239">239</biblScope>
<biblScope unit="page-count">13</biblScope>
<publisher>John Wiley & Sons, Ltd</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2011-07">2011-07</date>
</imprint>
<idno type="ISSN">1052-9276</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1052-9276</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Adult mice</term>
<term>Amphotropic</term>
<term>Amphotropic mulv</term>
<term>Anecdotal evidence</term>
<term>Autographa californica baculovirus</term>
<term>Available information</term>
<term>Baculovirus</term>
<term>Biological parameters</term>
<term>Biosafety</term>
<term>Bovine herpesvirus</term>
<term>Canarypox virus</term>
<term>Cancer gene therapy</term>
<term>Cancer patients</term>
<term>Cancer therapy</term>
<term>Cell lines</term>
<term>Cell surface receptor</term>
<term>Clinical application</term>
<term>Clinical applications</term>
<term>Clinical gene therapy</term>
<term>Clinical studies</term>
<term>Clinical trials</term>
<term>Containment measures</term>
<term>Copyright</term>
<term>Current gene therapy</term>
<term>Cytosine deaminase</term>
<term>Disease associations transmission</term>
<term>Endogenous viruses</term>
<term>Environmental risk</term>
<term>Environmental risk assessment</term>
<term>Environmental risk assessments</term>
<term>Environmental risks</term>
<term>Gene</term>
<term>Gene delivery</term>
<term>Gene therapy</term>
<term>Genetic information</term>
<term>Guideline</term>
<term>Herpesvirus</term>
<term>Hoeben</term>
<term>Host range</term>
<term>Host species</term>
<term>Human blood</term>
<term>Human cancer cells</term>
<term>Human cells</term>
<term>Human gene therapy</term>
<term>Human population</term>
<term>Human viruses</term>
<term>Infectious disease</term>
<term>Infectious progeny virus</term>
<term>Insect vector</term>
<term>Insect vector transmission</term>
<term>International european</term>
<term>John wiley sons</term>
<term>Limited capacity</term>
<term>Literature study</term>
<term>Little information</term>
<term>Long terminal</term>
<term>Mammalian cells</term>
<term>Many countries</term>
<term>Maraba</term>
<term>Maraba virus</term>
<term>Medium medium</term>
<term>Molecular cell biology</term>
<term>Molecular medicine</term>
<term>Molecular therapy</term>
<term>Mulv</term>
<term>Mulvs</term>
<term>Murine</term>
<term>Murine leukemia virus</term>
<term>Murine leukemia viruses</term>
<term>Narrow host range</term>
<term>Natural host</term>
<term>Neuroendocrine cancers</term>
<term>Newborn mice</term>
<term>Newcastle disease virus</term>
<term>Normal host species</term>
<term>Oncolytic</term>
<term>Oncolytic agent</term>
<term>Oncolytic virus</term>
<term>Oncolytic virus therapy</term>
<term>Oncolytic viruses</term>
<term>Porcine</term>
<term>Porcine population</term>
<term>Potential consequences</term>
<term>Practical procedures</term>
<term>Primates</term>
<term>Productive infection</term>
<term>Prophylactic treatment</term>
<term>Replication</term>
<term>Research activities</term>
<term>Retroviral vectors</term>
<term>Retrovirus</term>
<term>Rhesus monkeys</term>
<term>Risk assessment</term>
<term>Risk categories</term>
<term>Risk category</term>
<term>Risk management</term>
<term>Risk score</term>
<term>Seneca</term>
<term>Seneca valley</term>
<term>Seneca valley virus</term>
<term>Side effects</term>
<term>Solid tumors</term>
<term>Such activities</term>
<term>Such guidelines</term>
<term>Susceptible hosts</term>
<term>Therapeutic agent</term>
<term>Therapeutic agents</term>
<term>Therapeutic virus</term>
<term>Therapeutic viruses</term>
<term>Therapy</term>
<term>Tumor cells</term>
<term>Unintended exposure</term>
<term>Vaccine</term>
<term>Vesicular stomatitis virus</term>
<term>Viral</term>
<term>Virol</term>
<term>Virus</term>
<term>Virus incapacity</term>
<term>Virus species</term>
<term>Xenotransplantation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Viruses usually infect a restricted set of host species, and only in rare cases does productive infection occur outside the natural host range. Infection of a new host species can manifest as a distinct disease. In this respect, the use of non‐human viruses in clinical therapy may be a cause for concern. It could provide the opportunity for the viruses to adapt to the new host and be transferred to the recipient's relatives or medical caretakers, or even to the normal host species. Such environmental impact is evidently undesirable. To forecast future clinical use of non‐human viruses, a literature study was performed to identify the viruses that are being considered for application as therapeutic agents for use in humans. Twenty‐seven non‐human virus species were identified that are in (pre)clinical development, mainly as oncolytic agents. For risk management, it is essential that the potential environmental consequences are assessed before initiating clinical use, even if the virus is not formally classified as a genetically modified organism. To aid such assessment, each of these viruses was classified in one of five relative environmental risk categories, ranging from “Negligible” to “Very High”. Canary pox virus and the Autographa californica baculovirus were assigned a “Negligible” classification, and Seneca Valley virus, murine leukemia virus, and Maraba virus to the “High” category. A complicating factor in the classification is the scarcity of publicly available information on key aspects of virus biology in some species. In such cases the relative environmental risk score was increased as a precaution. Copyright © 2011 John Wiley & Sons, Ltd.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Pays-Bas</li>
</country>
<region>
<li>Hollande-Méridionale</li>
</region>
<settlement>
<li>Leyde</li>
</settlement>
</list>
<tree>
<country name="Pays-Bas">
<region name="Hollande-Méridionale">
<name sortKey="Koppers Alic, Danijela" sort="Koppers Alic, Danijela" uniqKey="Koppers Alic D" first="Danijela" last="Koppers-Lalic">Danijela Koppers-Lalic</name>
</region>
<name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
<name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
<name sortKey="Hoeben, Rob C" sort="Hoeben, Rob C" uniqKey="Hoeben R" first="Rob C." last="Hoeben">Rob C. Hoeben</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C78 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C78 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:ABA0CDBD2DCC8AA0A11B54C1B445C00EBB8EA660
   |texte=   Non‐human viruses developed as therapeutic agent for use in humans
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021